Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study

• Published in: EJD. European journal of dermatology Vol. 31; no. 2; pp. 217 - 224
• Main Authors: Giordano-Labadie, Françoise, Becherel, Pierre-André, Pralong, Pauline, Outtas, Omar, Ruer-Mulard, Mireille, Berard, Frédéric, Greco, Matthieu, Lacour, Jean-Philippe, Debons-Peyroutet, Michèle, Pelvet, Bérengère, Lamirand, Audrey, Guillet, Gérard
• Format: Journal Article
• Language: English
• Published: Paris JLE Éditions 01.04.2021; John Libbey Eurotext
• Subjects: Dermatology; Medicine; Medicine & Public Health; Therapy; angioedema; chronic inducible urticaria; H1-antihistamines; omalizumab; quality of life; chronic spontaneous urticaria
• ISSN: 1167-1122; 1952-4013; 1952-4013
• DOI: 10.1684/ejd.2021.4023

Background: It is important to assess the burden of chronic urticaria (CU) with real-life studies. The AWARE study was performed in 36 countries over two years in CU patients resistant to H1-antihistamines. Objectives. To correlate patient-reported outcomes and available therapeutic options in CU patients. Materials & Methods: The AWARE study was a prospective, non-interventional, international study that included adult patients who have had H1-antihistamine-resistant CU for at least two months. The primary endpoints were the evolution of disease activity (UAS7), urticaria control (UCT), dermatological quality of life (DLQI) and treatment satisfaction (visual analogic scale) during a two-year follow-up. The data from French centres are reported. Results: Ninety-two patients were included (mean age: 47.8 years; women: 70.7%; mean disease duration: 6.5 years; angioedema: 34.1%). The percentage of patients with CU treatment increased from 56.5% at inclusion to 86.0% after two years (for patients with non-sedative H1-antihistamines from 52.2% to 74.4%, and omalizumab from 2.2% to 25.6%). During the follow-up, the percentage of patients with UAS7 score <6 increased from 12.5% to 60.9%, and patients with well-controlled CU (UCT score >12) increased from 11.1% to 62.2%. The negative impact on quality of life (DLQI >10) decreased from 34.1% to 10.5%. The mean score of patient satisfaction for treatment increased from 4.6 to 7.6. Conclusion: The management of CU patients resistant to H1-antihistamines was not optimal at inclusion with uncontrolled disease, impaired quality of life and insufficient treatment. After a two-year follow-up, disease symptoms and quality of life improved, but the therapeutic management could be further optimized.